In a nutshell This trial is examining the effectiveness of crenolanib after salvage chemotherapy for relapsed or unresponsive acute myeloid leukemia (AML) with FLT3 activating mutations. The main outcome would be survival without complications from leukemia 3 years after the treatment has finished. The details AML is a type of blood...
Read MoreIn a nutshell This trial aims to investigate adding tocilizumab (Actemra) to treatment with ipilimumab (Yervoy) and nivolumab (Opdivo) for patients with advanced melanoma. The main outcome that will be measured is how the tumor size changes. The study is being conducted in New York, United States. The details...
Read More
In a nutshell This study is evaluating how well a new chemoimmunotherapy regimen works in treating patients with classical Hodgkin’s lymphoma (cHL) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer after treatment. This study...
Read More
In a nutshell This phase 3 study is evaluating the effectiveness and safety of two different chemotherapy regimens for patients with mantle cell lymphoma (MCL). The main outcome to be measured will be the number of patients who survive without tumor growth or spread. This study is recruiting in Las Vegas, Nevada in the U.S. The details MCL is an...
Read MoreIn a nutshell This phase 3 trial will investigate the effect of bupropion (Wellbutrin) to treat fatigue in patients with breast cancer (BC). The main outcomes will be fatigue, quality of life and depression. This trial is recruiting across the United States. The details After treatment for breast cancer (BC), many women report feeling...
Read More
In a nutshell This phase 1 trial will investigate the safety of an experimental drug, XmAb22841 (XmAb), to treat advanced cancer. The main outcome will be the safety and tolerability of XmAb. This study is recruiting in Georgia and Texas, USA. The details Advanced cancer can be difficult to treat. New drugs are being developed to...
Read More
In a nutshell This phase 1 trial will investigate the safety of an experimental drug, XmAb22841 (XmAb), to treat advanced cancer. The main outcome will be the safety and tolerability of XmAb. This study is recruiting in Georgia and Texas, USA. The details Advanced cancer can be difficult to treat. New drugs are being developed to address this. Immune...
Read More
In a nutshell This phase 1 trial will investigate the safety of an experimental drug, XmAb22841 (XmAb), to treat advanced cancer. The main outcome will be the safety and tolerability of XmAb. This study is recruiting in Georgia and Texas, USA. The details Advanced cancer can be difficult to treat. New drugs are being developed to address this. Immune...
Read More
In a nutshell This phase 1 trial will investigate the safety of an experimental drug, XmAb22841 (XmAb), to treat advanced cancer. The main outcome will be the safety and tolerability of XmAb. This study is recruiting in Georgia and Texas, USA. The details Advanced cancer can be difficult to treat. New drugs are being developed to address this....
Read More
In a nutshell This phase 1/2 trial is examining the effectiveness of a new immunotherapy in the treatment of patients with advanced colorectal cancer (CRC). The main outcome to be measured will be tumor response to the treatment. This study is being conducted in Texas, USA. The details CRC is the third most common cancer worldwide. The 5-year...
Read MoreIn a nutshell This trial is examining the effectiveness of plantar flexion training (PFT) in patients with stroke and impaired foot movement. The main outcome to be measured will be step length and muscle activity. This study is being conducted in Texas, US. The details A stroke consists of the death of brain cells due to lack of oxygen. This is...
Read MoreIn a nutshell This phase 1/2 trial will investigate the safety of 9-ING-41, for treatment-resistant cancers. The main outcome will be the number of treatment-related adverse events (TRAEs). This trial is recruiting in the United States. The details Some cancers may not respond to conventional treatment. Treatment-resistant cancers are called...
Read More
